Perioperative Apalutamide in High-Risk Localized Prostate Cancer (PROTEUS) @NEJMgroup
Perioperative Apalutamide in High-Risk Localized Prostate Cancer (PROTEUS) @NEJMgroup
Uploaded August 2026 | Updated September 2026, 1 week ago
In high-risk localized prostate cancer, ADT plus apalutamide led to a pathological complete response or minimal residual disease and 5-year metastasis-free survival in a greater percentage of patients than ADT plus placebo.

Read the full phase 3 PROTEUS trial results and Research Summary at NEJM.org.

#oncology #urology #nejm
Perioperative Apalutamide in High-Risk Localized Prostate Cancer (PROTEUS)How Physician Coaches Can Be BeneficialResponse-Tailored Antibiotic Treatment for Endocarditis (POET II)NEJM This Week — April 2, 2026Teclistamab in Previously Treated Multiple Myeloma (MajesTEC-9)NEJM Interview: Jean Nachega on the importance of investment in equitable partnerships, community...Ask the Expert: What’s the H2FPEF Score?Logistic Regression | NEJM EvidenceImage Challenge — July 23, 2026Original Article: Atezolizumab plus FOLFOX for Stage III Colon Cancer (ATOMIC)Dr. Glaucomflecken Explains: Clesrovimab for Prevention of RSV Disease in Healthy Infants (CLEVER)Images in Clinical Medicine: Bronchial Casts from Inhalation of Forest-Fire Smoke
NEJM Group |

Perioperative Apalutamide in High-Risk Localized Prostate Cancer (PROTEUS)

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER